Frusin40 mg

Frusin is a loop diuretic ("water pill") with FDA-approved and guideline-supported uses across several conditions:

Established / FDA-approved uses

• Edema associated with congestive heart failure, hepatic cirrhosis (liver disease), and renal disease, including the nephrotic syndrome.
• Acute pulmonary edema (fluid in the lungs), where intravenous Frusin is used for rapid symptom relief.
• Hypertension (high blood pressure) — Frusin may be used alone, but is more commonly used as part of combination therapy with other antihypertensive agents, especially in patients who also have edema or reduced kidney function.

Other / adjunct uses

• Adjunct management of hypertensive emergencies (hypertensive crisis) alongside other agents.
• Adjunctive use in acute hypercalcemia (after adequate volume replacement), typically as part of hospital-based management.

The specific dose and form (tablet, oral solution, or injection) depend on the indication and severity — see Dosage and Administration.

Each Furosemide tablet, oral solution, or injection contains Furosemide as the active pharmaceutical ingredient. Common strengths marketed include:

• Oral tablets: 20 mg and 40 mg (higher strengths such as 80 mg or 500 mg exist for select markets/indications)
• Oral solution: 10 mg/mL or 20 mg/5 mL
• Injection (IM/IV): 10 mg/mL (commonly supplied as 20 mg/2 mL ampoules)

Formulations also contain standard pharmaceutical excipients that do not affect the therapeutic action of Furosemide.

Frusin is a potent loop diuretic (a "water pill") belonging to the sulfonamide-derivative class of drugs, chemically distinct from thiazide diuretics. It is one of the most widely used diuretics worldwide because of its rapid onset and strong ("high-ceiling") diuretic effect, even in patients with reduced kidney function.

Frusin works by increasing the excretion of salt (sodium and chloride) and water by the kidneys, which reduces fluid overload in conditions such as heart failure, liver disease, and kidney disease, and helps lower blood pressure. It is available as oral tablets, an oral solution, and an injectable form for use when rapid or parenteral therapy is required.

Frusin belongs to the loop diuretic (high-ceiling diuretic) class, a sulfonamide-derivative group of medicines distinct from thiazide and potassium-sparing diuretics.

Mechanism of Action

Furosemide acts primarily on the thick ascending limb of the loop of Henle in the kidney, where it inhibits the Na⁺/K⁺/2Cl^- co-transporter. This blocks reabsorption of sodium, potassium, and chloride, leading to a marked increase in excretion of these electrolytes along with water. Furosemide also increases excretion of calcium and magnesium.

Pharmacokinetics

• Onset: Oral — within about 30–60 minutes; Intravenous — within about 5 minutes.
• Duration: Oral — approximately 6–8 hours; Intravenous — approximately 2 hours.
• Protein binding: Highly protein-bound (>95%), mainly to albumin.
• Metabolism/Excretion: Primarily excreted unchanged by the kidneys via active tubular secretion and glomerular filtration; a smaller portion is metabolized in the liver.

Frusin tablets/solution may be taken with or without food, generally in the morning (and, if a second dose is needed, in the early afternoon) to avoid nighttime urination. Swallow tablets with a glass of water; the oral solution should be measured with an accurate dosing device. The injectable form of Frusin is administered by a healthcare professional intravenously (slowly) or intramuscularly. Do not increase the dose or frequency on your own — take Frusin exactly as prescribed.

Frusin has several clinically significant drug interactions:

• Aminoglycoside antibiotics (e.g., gentamicin): Increased risk of ototoxicity (hearing damage) and nephrotoxicity when combined with Frusin; avoid concurrent use except in life-threatening situations.
• Digoxin: Frusin-induced hypokalemia (low potassium) increases the risk of digoxin toxicity and cardiac arrhythmias; electrolytes should be monitored closely.
• Lithium: Frusin reduces renal clearance of lithium, increasing the risk of lithium toxicity; lithium levels should be monitored.
• NSAIDs (e.g., ibuprofen, indomethacin): May reduce the diuretic and antihypertensive effect of Frusin and increase the risk of kidney impairment, particularly in dehydrated or elderly patients.
• ACE inhibitors / ARBs: Combination with Frusin can cause a significant drop in blood pressure and acute kidney injury, especially when starting therapy or in volume-depleted patients.
• Other antihypertensive agents: Additive blood-pressure-lowering effect; dose adjustment of other agents may be needed.
• Corticosteroids: Additive risk of hypokalemia with concurrent use.
• Ethacrynic acid: Concurrent use with Frusin is associated with a significantly increased risk of ototoxicity and should generally be avoided.
• Lithium, cisplatin, and other nephrotoxic/ototoxic drugs: Increased risk of toxicity when combined with Frusin.

Side effects of Frusin are generally dose-related and most often reflect its diuretic and electrolyte-depleting action.

Common

• Electrolyte disturbances: hypokalemia (low potassium), hyponatremia (low sodium), hypomagnesemia, hypochloremic alkalosis
• Dehydration and volume depletion, dizziness, headache
• Hypotension (low blood pressure), particularly postural (dizziness on standing)
• Increased blood glucose (hyperglycemia) and increased uric acid (hyperuricemia), which may precipitate gout
• Nausea, vomiting, diarrhea, constipation

Less common but serious

• Ototoxicity (tinnitus, hearing loss — usually reversible), especially with rapid IV administration, high doses, or severe renal impairment
• Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) — rare
• Blood disorders (aplastic anemia, thrombocytopenia, leukopenia) — rare
• Pancreatitis, jaundice, hepatic encephalopathy in susceptible patients
• Interstitial nephritis, vasculitis

Pregnancy: Frusin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Animal studies have shown adverse effects at high doses, and adequate, well-controlled human studies are lacking; fetal growth should be monitored if Frusin is used during pregnancy. Always consult a physician before using Frusin during pregnancy.

Lactation: Frusin passes into breast milk and may inhibit lactation (milk production). Use during breastfeeding should occur only under medical supervision, weighing the benefit to the mother against potential risk to the infant; consult a physician before use.

Frusin requires careful monitoring during use:

• Fluid and electrolyte balance: Frusin can cause profound diuresis with water and electrolyte depletion; monitor serum electrolytes (sodium, potassium, magnesium, chloride), renal function (BUN/creatinine), and fluid status periodically, especially at the start of therapy and with dose changes.
• Ototoxicity: Risk increases with rapid IV injection, high doses, and severe renal impairment, or when combined with other ototoxic drugs; administer IV doses slowly.
• Hepatic disease: In patients with cirrhosis, Frusin therapy should be initiated in a hospital setting due to the risk of precipitating hepatic coma from electrolyte imbalance; use the smallest effective dose.
• Diabetes and gout: Frusin may raise blood glucose and uric acid levels; monitor patients with diabetes or a history of gout.
• Renal function: Discontinue if increasing azotemia and oliguria occur during treatment of severe progressive renal disease.
• Sulfonamide sensitivity: Use with caution in patients with a known sulfonamide allergy due to possible cross-sensitivity.
• Hearing and dehydration symptoms: Report symptoms such as thirst, dry mouth, weakness, lethargy, muscle cramps, or lightheadedness promptly to a physician.

Overdose of Frusin can cause profound diuresis leading to dehydration, blood volume depletion, hypotension, electrolyte imbalance (particularly hypokalemia and hypochloremic alkalosis), and circulatory collapse. Symptoms may include severe thirst, weakness, dizziness, confusion, muscle cramps, low blood pressure, and reduced urine output.

If an overdose of Frusin is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive, focusing on fluid and electrolyte replacement and monitoring under medical supervision; do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children. Do not use tablets that have changed color.

• Renal impairment: Frusin remains effective but may require higher individual doses to achieve adequate diuresis; close monitoring of renal function and electrolytes is required.
• Hepatic impairment: Use with caution; initiate in hospital in patients with cirrhosis and ascites due to risk of hepatic coma (see Contraindications and Precautions).
• Elderly patients: Start at the lower end of the dosing range due to age-related decline in renal, hepatic, and cardiac function; monitor closely for dehydration, electrolyte disturbance, and hypotension (falls risk).
• Diabetic patients: Frusin may increase blood glucose; monitor glycemic control.
• Patients with gout or hyperuricemia: Monitor uric acid levels, as Frusin can precipitate gout attacks.
• Premature infants: Use with caution; Frusin has been associated with nephrocalcinosis/nephrolithiasis in premature infants and may increase the risk of persistent patent ductus arteriosus — see Pediatric Uses.

Duration of Frusin therapy depends on the underlying condition. Acute pulmonary edema typically requires only short-term (days) use, while chronic conditions such as heart failure, cirrhosis with ascites, or chronic kidney disease may require long-term, ongoing therapy with periodic dose adjustment. Frusin for hypertension is generally continued long-term as part of an overall treatment plan. Treatment duration and the need for continued therapy should always be determined by the prescribing physician based on clinical response and regular monitoring.

Furosemide is classified as a loop diuretic (high-ceiling diuretic), within the broader sulfonamide-derivative (non-antibacterial) chemical class of medicines.

Furosemide inhibits the Na⁺/K⁺/2Cl^- co-transporter (NKCC2) located on the luminal membrane of the thick ascending limb of the loop of Henle in the nephron. By blocking this transporter, Furosemide prevents reabsorption of sodium, potassium, and chloride ions, which increases their excretion, along with obligatory water, into the urine. This produces a rapid and pronounced ("high-ceiling") diuretic effect, even in patients with reduced glomerular filtration rate. Furosemide also promotes renal excretion of calcium and magnesium and has some direct venodilatory effect that can provide rapid symptomatic relief in acute pulmonary edema, prior to the onset of diuresis.

C

Frusin is used in children for the treatment of edema associated with congestive heart failure, renal disease (including nephrotic syndrome), and hepatic disease, using weight-based dosing (initial 2 mg/kg orally as a single dose, increased cautiously by 1–2 mg/kg no sooner than every 6–8 hours; not to exceed 6 mg/kg/day) under close physician supervision.

Use in premature infants requires particular caution: Frusin has been associated with nephrocalcinosis/nephrolithiasis and may increase the risk of a persistent patent ductus arteriosus when given in the first weeks of life; renal function and, where appropriate, renal ultrasonography should be monitored. Safety and efficacy for indications outside these established uses have not been fully established in all pediatric age groups, and pediatric use should always be guided and monitored by a physician.